Introduction
Rhabdomyosarcoma is the most common soft tissue tumor in children and adolescence, accounting for 4-5% of pediatric tumors. The two common histiotypes are a favorable group comprising embryonal rhabdomyosarcoma (eRMS) and an unfavorable group comprising alveolar rhabdomyosarcoma (aRMS) (1) . Standard therapeutic regimens are a combination of vincristine, actinomycin-D and cyclophosphamide, with other drugs being tested in clinical trials (2) . Although the introduction of chemotherapy has greatly improved survival, overall survival rate is 70%, which indicates that new chemotherapeutic approaches need to be developed (3) .
Tumor metabolism is receiving ever-increasing attention as an anti-tumor target.
Several metabolic pathways function differently in tumor and non-transformed cells (4).
In particular, glycolysis is frequently upregulated in tumor cells, and respiration is inhibited. This makes tumor cells particularly sensitive to glycolytic inhibitors such as 2-deoxyglucose (2-DG) or 3-bromopyruvate (5, 6) . Some pieces of evidence suggest that targeting glycolysis could be a good strategy against rhabdomyosarcoma. These cells display mitochondrial respiratory defects (7) and an energy producing metabolic phenotype compared to a more catabolic metabolism of primary myocytes (8) . This could be due to hyperactivation of the PI3K/Akt/mTOR pathway, which is frequently observed in rhabdomyosarcoma (9) . Second, p53 is frequently inactivated in rhabdomyosarcoma (10) . p53 sustains the production of ATP through respiration, and its loss promotes glycolysis. Therefore, loss of p53 has been shown to promote susceptibility of tumor cells to glucose deprivation (11) . Additionally, rhabdomyosarcoma can be detected in patients using the PET technique, which is based on uptake of a glucose analog (12) . Sensitivity to antiglycolytics is known to be regulated by a number of proteins involved in response to metabolic stress. However, little is known about the cell death proteins that respond to these drugs (13) . Cell death in animals occurs mainly through apoptosis or necrosis; these forms of cell death promote different responses in the tissue, with necrosis being a pro-inflammatory form of cell death, as opposed to apoptosis (14) .
Regarding apoptosis, two major pathways have been described: the extrinsic, death ligand-mediated pathway, and the intrinsic or mitochondrial pathway (15) . The first pathway is initiated by death ligands such as TNF, Fas Ligand or TRAIL, and is mediated by the protease Caspase-8. The mitochondrial pathway is initiated by "BH3-only" proteins such as Bim, Noxa or Puma, which act as stress sensors and promote activation of Bax and Bak on the mitochondrial membrane. This allows the release of cytochrome c which promotes formation of the apoptosome and caspase activation.
We aimed to determine whether rhabdomyosarcoma cells are sensitive to the glycolytic inhibitor 2-deoxyglucose. We describe that alveolar rhabdomyosarcoma cells are sensitive to this drug. Moreover, we provide evidence that the BH3-protein Noxa mediates apoptosis. For treatments, cells were plated at a concentration of 200,000/ml and treated in fresh medium 24h later at 70% confluence (600,000/ml). Q-VD-OPH (SM Biochemicals LLC, CA) was used at 20μM and added at the time of addition of 2-deoxyglucose. An equal amount of DMSO was added to the controls.
MATERIALS AND METHODS

Cell culture and treatments
Western blots
Cells were trypsinized, washed with PBS, lysed by resuspending them in lysis buffer (5mM Tris-ClH/ 2% SDS, Complete antiprotease cocktail (Roche)) and frozen. For analysis of phospho-proteins and HIF-1α cells were lysed in RIPA buffer plus orthovanadate and 2-glycerol-phosphate. After sonication, protein concentration was measured with BCA (Pierce). Equal amounts of protein were mixed with Laemmli loading buffer. After electrophoresis, protein was transferred to a PVDF membrane (Millipore).
Membrane was blocked with 5% nonfat dry milk in TBS-tween (0.1%). Antibodies are detailed in Supplementary Methods.
Immunocytochemistry
Attached and detached cells were collected by trypsinization, fixed in suspension with 4% paraformaldehyde in PBS for 20 min at room temperature, washed and blocked with 0.1% BSA+ 0.1% Triton X-100 in PBS for 1h. Then they were incubated overnight with anti-active Bax (6A7, 556467, BD Pharmingen, 1:100) or anti-active Bak (Calbiochem /Merck Ab-1/TC100) diluted in blocking buffer. See more details in Supplementary Methods.
Immunoprecipitations
Attached cells were collected by trypsinization and washed in PBS together with detached cells. They were lysed in 500 μl of CHAPS immunoprecipitation buffer (2% CHAPS, 20mM Tris/HCl (pH 7.4), 137mM NaCl, 2mM EDTA, 10% glycerol) plus Complete protein inhibitors (Roche) for 30 min. 30 µl of Protein G Magnetic Beads (Millipore) were washed 3x in immunoprecipitation buffer without CHAPS and then incubated in 1ml of CHAPS buffer with 2µg of antibody for 4h at 4ºC under rotation. 500µg of total cell extract was incubated overnight in 1ml of beads coupled with 2µg of antibody. The next day, beads were washed three times with immunoprecipitation buffer and incubated with 45 μl of immunoprecipitation buffer containing 2% SDS and 15 μl of SDS loading buffer (containing 5% beta-mercaptoethanol), for 10 min at 95°C. Eluted proteins were subjected to SDS-polyacrylamide gel electrophoresis.
Measurement of cell death
For sub-G1 analysis, detached and attached cells were trypsinized, washed in PBS, 
RT-PCR
Total RNA (3 μg), extracted using the Nucleospin RNA II kit (Macherey-Nagel), was used for cDNA synthesis with SuperScript II Reverse Transcriptase (Invitrogen). though glucose is present at 25mM in the culture medium (Suppl. Fig. S1 ). We observed cell death at doses over 5mM (Fig.1A) . Cell death was likely due to apoptosis because DNA was degraded and cells displayed sub-G1 DNA content. Furthermore, DNA cleavage was prevented by incubating cells in the presence of the caspase inhibitor Q-VD. The same results were observed in Rh30 or Rh41 aRMS cell lines ( Fig.1 B and C) .
Embryonal rhabdomyosarcoma (eRMS) generally have a better prognosis than aRMS. We observed that eRMS RD and A-204 cells were much more resistant than aRMS to 2-DG. RD cells only showed cell death at high doses, almost equimolar with glucose concentration in the medium (Fig.1D) . A-204 cells were completely resistant at all doses tested (Fig.1E) . We did however observe inhibition of cell growth at higher doses (Fig. 1F) .
In order to determine whether this cell growth arrest was irreversible, after 72h cells were washed and they were left growing in the absence of 2-DG. Cell growth arrest was reversible, since cells started growing back immediately after removing the drug (Fig. 1F ).
Since HIF-1α frequently regulates tumor glycolytic phenotype, one possibility was that HIF-1α was differentially expressed in eRMS versus aRMS and it could be regulating uptake and toxicity of 2-DG in rhabdomyosarcomas. Thus, we analyzed the levels of this treatment, the levels of this protein did not increase, and its downregulation using siRNA did not protect from 2-DG. Rather, a slight sensitization was observed (Suppl. Fig. S2 ).
Although aRMS express markers of muscular differentiation they lack the possibility of terminal differentiation, what is believed to be caused by PAX/FOXO1a chimeras (17, 18) . Since differentiated cells stop proliferating, one of the aims of the therapy is to promote differentiation of the tumor cells. We observed fusion of aRMS cells characteristic of myotube formation and terminal differentiation after treatment with 2-DG ( Fig.2A and Suppl. Fig.S1 ). This was likely due to the fact that 2-DG induced the downregulation of the fusion protein PAX3/FOXO1a (Fig.2B) , what promotes diffrentiation of these cells (17) . This effect was more pronounced when cells were cultured in differentiation medium (without serum) and was not inhibited by the caspase inhibitor Q-VD, indicating that differentiation was not a consequence of caspase activity.
2-deoxyglucose induces apoptotic cell death
Inhibition of glucose metabolism induces cell death by necrosis or by apoptosis, probably depending on the cell type (13) . Results shown in Fig. 1 suggest that the form of cell death is apoptosis, since death is inhibited by the caspase inhibitor Q-VD. However, we were unable to detect cleavage of caspase-3 by western blot (not shown). In order to verify that cell death is apoptosis we analyzed cleavage of the caspase substrate poly-(ADP-ribose)polymerase (PARP). Treatment with 2-DG promoted PARP cleavage which was inhibited b Q-VD (Fig.3A) . Moreover, 2-DG induced caspase activity as measured by cleavage of a peptidic caspase substrate (Fig. 3B) . Additionally, we analyzed the nuclear morphology of Rh4 cells after treatment with 2-DG and we observed classical apoptotic chromatin condensation (Fig.3C ). 
Apoptosis induced by 2-deoxyglucose proceeds through the mitochondrial pathway
In hematopoietic cells, apoptosis induced by glucose deprivation proceeds through the mitochondrial pathway (13) . However, we have described that in other cell types apoptosis induced by lack of glucose is mediated by caspase-8 and it does not require a functional mitochondrial apoptotic pathway (19). We observed that the most sensitive cell lines did not express detectable caspase-8 (Suppl. Fig. S3 ). We thus analyzed the mitochondrial pathway by immunostaining with antibodies that detect the active forms of Bax and Bak, the proteins that mediate mitochondrial permeabilization during apoptosis.
As shown in Fig. 3C , 2-DG promoted Bax and Bak activation even when cells were treated in the presence of Q-VD, indicating that these events are not a consequence of caspase activity.
In order to further demonstrate the involvement of the mitochondrial pathway in death by 2-DG, we overexpressed the anti-apoptotic Bcl-2 homologs Bcl-xL and Mcl-1 in Rh4 cells (Fig. 4A,B and Suppl. Fig. S4,S5 ). Both proteins prevented death induced by 2-DG. Conversely, downregulation of these proteins sensitized cells to 2-DG (Fig. 4C, 4D and S5). (Fig. 4E) . Levels of other anti-apoptotic Bcl-2 family members (Bcl-2 and Bcl-xL) increased during treatment, while Bax and Bak did not change significantly. We analyzed the levels of putative BH3-only proteins which could be responsible for cell death induced by 2-DG (Fig. 5A) . We observed that PUMA was not (Fig. 5B and S5 ). As shown in Fig.   5C , siRNA-mediated ablation of Noxa but not Bim conferred significant resistance to 2-DG.
The combined ablation of the two proteins did not confer further resistance to cell death, indicating that Noxa is the major cell death mediator.
Noxa is constitutively bound to Mcl-1 in many cell lines, and it has also been described to be bound to Bcl-xL (22). These antiapoptotic proteins can also sequester Bak and Bax. Pro-apoptotic proteins such as Noxa can free Bax/Bak allowing them to promote cytochrome c release. We studied interactions between these proteins and we observed that Mcl-1 is constitutively bound to Bim and Noxa (Fig. 5D, 5E ). Additionally, we could detect very weakly interactions between Bak and Bcl-xL or Mcl-1 ( Fig. 5F and Suppl. The Noxa/Mcl-1 axis has been described to be involved in cell death induced by inhibition of cell metabolism, and its levels and activity have been shown to be regulated by multiple transcriptional and post-transcriptional mechanisms (21, 23-25). We checked for transcriptional regulation and we observed that mRNA levels of these proteins barely changed (Fig 6A) . By blocking protein synthesis with cycloheximide we observed that stability of the short-lived Mcl-1 and Noxa was dramatically enhanced when cells were treated with 2-DG (Fig 6B) 
(dephosphorylation) of the marker of mTOR status S6 (Fig. 6C) . Additionally, we observed that Noxa was contributing modestly to downregulation of Mcl-1 (Fig. 6D) .
Endoplasmic reticulum stress, but not ATP loss, correlates with apoptosis and regulation of Noxa and Mcl-1.
Glucose deprivation and 2-DG impair generation of ATP, synthesis of macromolecules and protein modifications such as acetylation and glycosylation. While 2-DG is frequently used as a caloric restriction mimic, it has been shown to kill some tumor cell lines by interference with protein N-glycosylation rather than by causing energetic stress (27). We aimed to identify the major cause of death induced by 2-DG by incubating cells in the presence of the sugar mannose, which rescues some cell lines from the toxicity of 2-DG by restoring glycosylation. We observed that co-incubation with mannose completely prevented cell death induced by 2-DG (Fig. 7A ). This suggested that death was due to impairment of glycosylation in the endoplasmic reticulum (ER) and the subsequent ER stress. We indeed observed induction of several ER stress markers such as ATF4/CREB2, GRP58 and the ER chaperones GRP94/endoplasmin and GRP78/BiP (Fig. 7B) .
Mannose fully prevented the induction of these proteins. Moreover, mannose prevented accumulation of Noxa and loss of Mcl-1, and it reduced the induction of Bim (Fig. 7B) . In order to verify that mannose was not interfering with all effects of 2-DG, for instance by reducing its uptake or providing metabolites for mitochondrial oxidation, we measured the effects of mannose on ATP depletion. As shown in figure 7C , 2-DG promoted a reduction of ATP levels that was not prevented by the addition of mannose. These results suggest that the Noxa/Mcl-1 axis is involved in ER-stress-induced apoptosis. To further analyze this, we treated the cells with the ER stressor tunicamycin at a dose that promoted cell death with the same kinetic as 2-DG (Fig. 7D) . We observed that 
tunicamycin also promoted a late increase in Noxa levels and a rapid decrease in Mcl-1.
Moreover, we downregulated the transcription factor ATF4 which is induced by the PERK ER stress pathway. ATF4 downregulation did not prevent Noxa increase (not shown) but it partially prevented cell death and loss of Mcl-1 (Fig. 7E and F) . According to our results, HIF-1α does not seem to be mediating the differential response to 2-DG either (Suppl. Fig. S2 ). We did however observe a small but reproducible sensitization to 2-DG when HIF-1α was downregulated, in accordance to studies by Lampidis and colleagues which indicate that HIF-1 protects cells under hypoxia from 2-DG (31).
In this work we have used the most commonly used glycolytic inhibitor, 2- deoxyglucose, that has been tested in clinical trials and has been proven well tolerated by patients (32) . Other drugs that target glycolysis are being tested in preclinical models, and may prove more effective in the future (4). Furthermore, it is possible that this drug would be more effective in combination regimes, since 2-DG synergizes with chemo and radio-therapy in vitro and in vivo. However, recent studies indicate that toxicity of 2-DG may be due to different effects than the absence of glucose. 2-DG inhibits glycolysis and usage of glucose to produce ATP or fatty acids. However, 2-DG can be metabolized through the pentose phosphate pathway in some conditions (34) , and a catalytic block does not sufficiently explain the toxicity of 2-DG (35). Moreover, 2-DG alters protein glycosylation in a different manner than glucose deprivation: while it inhibits N-glycosylation, it enhances O-GlcNAcylation. 2-DG has been shown to kill some cells in normoxia by inhibition of N-glycosylation and the subsequent endoplasmic reticulum (ER) stress, rather than by inhibition of glycolysis (27).
Our experiments indicate that ER stress mediates rhabdomyosarcoma cell death, since a sugar that reverts the effects of 2-DG on N-glycosylation, mannose (36) , completely protected from cell death, and inhibition of the ATF4 ER stress pathway partially prevented apoptosis. Inhibition of glycolysis does not appear to be critical for the toxicity of 2-DG over rhabdomyosarcoma. The fact that mannose did not prevent ATP loss induced by 2-DG rules out the possibility that mannose prevents death because it is being metabolized and used as a glycolytic intermediate. Indeed, Lampidis and colleagues showed that mannose cannot revert 2-DG toxicity in anaerobic conditions, in which cells are more dependent on glucose and toxicity of 2-DG would be primarily due to inhibition of anaerobic glycolysis (27). The apoptotic mechanism by which 2-DG induces cell death has remained underexplored even though this compound has been used in clinical trials. Apoptosis induced by glucose deprivation in hematopoietic cells is inhibited by overexpression of Bcl-2 or Bcl-xL and it has been shown to be mediated by Noxa, PUMA or Bim (20, 25). We could not detect induction of PUMA, possibly because this protein is usually induced in a p53 dependent manner but the aRMS cells used in this study are deficient in p53 (29, 30).
Consistent with data that suggest that death induced by 2-DG is due to ER stress we observed induction of Bim, which mediates death induced by ER stress in some systems (37) . However, when Bim accumulation was prevented by RNAi, no effect on cell death induced by 2-DG was observed (Fig. 6) . Moreover, Bim induction was only partially prevented by mannose, although this sugar completely prevented cell death.
We observed that Noxa was critical for cell death. Noxa is a well studied BH3-only protein which has recently been described to play a role in glucose metabolism by promoting glucose uptake but directing glucose flux away from the glycolytic pathway by a yet uncharacterized mechanism (23). Noxa/PMAIP1 mRNA had been observed to be induced in response to 2-deoxyglucose (38) , but its role in cell death had not been tested.
Additionally, Noxa has been shown to mediate death by ER stressors (22). In our studies, both Noxa induction and loss of Mcl-1 seem to be a consequence of ER stress rather than energetic stress, since addition of mannose prevented both events (Fig. 7B) . Regulation of both proteins was post-transcriptional. In the case of Noxa, its induction is only observed at long time points (3 days), while we can detect 40% death at 48h. This suggests that Additionally, other BH3-only proteins may also participate in the induction of apoptosis.
Altogether, our results suggest that expression of Noxa could predict sensitivity to antiglycolytic drugs, that inhibition of glycolysis could be an effective novel strategy to treat alveolar rhabdomyosarcoma, and that anti-glycolytic drugs should be further tested in clinical trials against this type of tumors. 
